Monday January 27, 2020

What price a cure?

The number of hugely expensive drugs to treat rare diseases is increasing but can we afford them?

Susan Mitchell

Deputy Editor and Health Editor

6th December, 2015

Martin Shkreli recently gained widespread opprobrium when his company raised the price of Daraprim, a 62-year-old old drug used to treat Aids patients, by 5,000 per cent to more than $750 a pill.

The pricing strategy by Shkreli’s Turing Pharmaceuticals infuriated the public. Suddenly, pharmaceutical pricing entered the presidential debate in the US.

Billionaire Donald Trump, the Republican presidential frontrunner, called Shkreli a “spoiled brat”, while Democratic frontrunner Hillary Clinton tweeted about it as a...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader



Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.



€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.




90 Day Pass

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

The genetic data harvesting company posted the results as calls were made for the Irish government to appoint a genomics medicine guru

Killian Woods | 1 day ago

The HSE has a funding crisis. Unless it is solved, the Sláintecare health reform programme cannot be implemented

Tony O'Brien | 1 day ago

As we celebrate the year of the International Year of the Nurse and Midwife, Susan Kent explores Florence Nightingale’s impact on healthcare – and the lessons modern Irish health policy could take from her approach

Susan Kent | 1 day ago